- Home
- BNKK vs GDTC Comparison
BNKK vs GDTC Comparison
Compare BNKK & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNKK | GDTC |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | Singapore |
| Employees | 8 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BNKK | GDTC |
|---|---|---|
| Price | $2.75 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 50.8K | 7.0K |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.73 |
| 52 Week High | $7.19 | $3.68 |
Technical Indicators
Market Signals| Indicator | BNKK | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 45.92 |
| Support Level | $2.64 | $0.97 |
| Resistance Level | $2.88 | $1.06 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 71.85 | 61.93 |
Price Performance
Historical ComparisonAbout BNKK Bonk Inc.
Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.